Navigation Links
Shire plc: Board Changes
Date:12/13/2007

rong returns for shareholders, with the company's market capitalisation rising from GBP1.7 billion in March 2003 to its current GBP6.6 billion. Matt will make an excellent non-executive Chairman and we are delighted that he will continue to play an important part in Shire's continued success.

"Angus will make a strong Chief Executive and has both considerable experience of Shire and the pharmaceutical industry in general. He, with Matt, has been instrumental in guiding Shire's successful development and creating such good returns for shareholders. Maintaining continuity for a successful specialty biopharmaceutical company in a dynamic industry will we believe protect and develop the Company and future returns to shareholders."

Matthew Emmens commented:

"I would like to thank Dr Cavanaugh for his guidance over many years at Shire. During the time we have worked together, Shire has made great progress. I am delighted at the prospect of becoming non-executive Chairman of the Group and supporting Angus in his new role, for which he is very well qualified. The support of David Kappler will also prove invaluable. Shire has a clear strategy, a differentiated pharmaceutical business model and is well positioned to take advantage of the many opportunities in its markets. To date, the success of this strategy is demonstrated by a strong performance, reflected in our recently announced upgraded guidance for revenue growth for 2007."

Notes to Editors

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisi
'/>"/>

SOURCE Shire PLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. KGI Elects Three New Members to Board of Trustees
8. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
9. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. BioLife Solutions Expands Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... Texas (PRWEB) September 20, 2014 ... integrated urological and interventional radiology products and services, ... Inc. subsidiary with Clinicon Corporation for ... expands HealthTronics’ portfolio of minimally invasive, mobile, surgical ... patients. , Under the agreement, HealthTronics will make ...
(Date:9/19/2014)... crop yields to disease risks, the biological characteristics people ... Just as for heightthe textbook example of a complex ... shaped by multiple genetic and environmental influences, making it ... such genes, geneticists typically mate two individuals that differ ... small mouseand then study their descendents, looking for genes ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... and its potential to revolutionize the world has ... multinational corporations and small start-ups. The early years ... research projects largely due to the high risks ... Government budgets earmarked for this evolving technology have ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... Administration (FDA) review, the Company is initiating ... administration of REOLYSIN(R) in,combination with paclitaxel and ... cancers. The Principal Investigator is Dr. Monica ...
... but powerful engine that propels the bacterium Bacillus ... flagellum by a protein clutch, Indiana University Bloomington and ... this week,s Science . , Scientists have ... what causes the flagellum to stop spinning -- temporarily ...
... As President Of ... AeroLEF Division -, ... , TSX: YM, AIM: YMBA), an oncology company that identifies,develops and ... imposed by the US Food and Drug,Administration (FDA) on the development ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3Microscopic 'clutch' puts flagellum in neutral 2Microscopic 'clutch' puts flagellum in neutral 3YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL 2YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL 3
(Date:9/19/2014)... regulate their symbiotic relationship with soil bacteria by ... plant structure from leaves into the roots to ... roots. This collaborative study was conducted by researchers ... Graduate University for Advanced Studies (SOKENDAI), and the ... , Legumes, an important plant family which ...
(Date:9/18/2014)... Miranda, a small, icy moon of Uranus, is one ... the solar system. Despite its relatively small size, Miranda ... that resulted in the formation of at least three ... coronae. , These coronae are visible in Miranda,s ... km across. Arden corona, the largest, has ridges and ...
(Date:9/18/2014)... "frequent flyers" program, fruit flies surely would be eligible ... increasing numbers of fruit fly research studies. One fruit ... and another is scheduled launch to the station Sept. ... December. , Fruit flies are biomedical research models studied ... organisms can reveal the basis for health and disease ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... of the tyrannosaurid, says a University of Alberta researcher ... turn the animal into a "zoological superweapon." , ... tyrannosaurids," said Dr. Eric Snively, a post doctoral research ... instance, was keeping the T. rexes from breaking their ...
... is virus as for example HIV and bird flu able ... the purpose of the virus? Researchers at the University of ... is a collaboration between molecular biologists and physicists. ”The molecular ... the interplay between the intercellular parts, while the physicists have ...
... get older. As sleep quality and quantity typically decrease ... a healthy older man gets can affect his level of ... the April 1st issue of the journal SLEEP. , The ... of Chicago, focused on 12 healthy men between the ages ...
Cached Biology News:Fused nasal bones helped tyrannosaurids dismember prey 2Danish researches solve virus puzzle 2
... AutoGen AutoGenesys, BioRobotics BioPick, BioGrid, TAS and ... systems This CLS number is a new ... product number. If showing no availability yet, ... (D9314) or contact customer service for assistance. ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... these culture chambers produce cell yields in ... range and are useful alternatives to multiple ... mechanical • strength and structural integrity • ... Certified nonpyrogenic and sterilized by gamma irradiation, ...
BD BioCoat Laminin 150 mm Culture Dishes...
Biology Products: